UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 91

Sortiert nach

Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy

Haematologica (Roma), 2014-03, Vol.99 (3), p.458

2014

Link zum Volltext

Verfügbarkeit prüfen

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors

Cancer medicine (Malden, MA), 2019-09, Vol.8 (11), p.5173-5182

2019

Link zum Volltext

Verfügbarkeit prüfen

Relevance of treatment‐free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitors

Cancer medicine (Malden, MA), 2021-06, Vol.10 (11), p.3635-3645

2021

Link zum Volltext

Verfügbarkeit prüfen

Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era: the French experience

Haematologica (Roma), 2011-09, Vol.96 (9), p.1276-1283

2011

Link zum Volltext

Verfügbarkeit prüfen

Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission

Cancer medicine (Malden, MA), 2019-09, Vol.8 (11), p.4976-4985

2019

Link zum Volltext

Verfügbarkeit prüfen

Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta‐analysis of studies over the last ten years

British journal of haematology, 2020-05, Vol.189 (3), p.452-468

2020

Link zum Volltext

Verfügbarkeit prüfen

A case of acute promyelocytic leukaemia with unusual cytological features and a ZBTB16‐RARA fusion gene

British journal of haematology, 2016-08, Vol.174 (4), p.502-502

2016

Link zum Volltext

Verfügbarkeit prüfen

Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells

Blood, 2011-08, Vol.118 (8), p.2211-2221

2011

Link zum Volltext

Verfügbarkeit prüfen

Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients

British journal of haematology, 2024-04, Vol.204 (4), p.1536-1539

2024

Link zum Volltext

Verfügbarkeit prüfen

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia

Blood, 2008-09, Vol.112 (5), p.2024-2027

2008

Link zum Volltext

Verfügbarkeit prüfen

Deep molecular responses for treatment‐free remission in chronic myeloid leukemia

Cancer medicine (Malden, MA), 2016-09, Vol.5 (9), p.2398-2411

2016

Link zum Volltext

Verfügbarkeit prüfen

Achieving a Complete Molecular Remission Under Imatinib Therapy Is Associated with a Better Outcome in Chronic Phase Chronic Myeloid Leukaemia Patients On Imatinib Frontline Therapy

Blood, 2012-11, Vol.120 (21), p.3754-3754

2012

Link zum Volltext

Verfügbarkeit prüfen

Transient abnormal myelopoiesis (TAM) in a neonate without Down syndrome

British journal of haematology, 2015-01, Vol.168 (1), p.2-2

2015

Link zum Volltext

Verfügbarkeit prüfen

A More Sensitive RQ-PCR to Assess Complete Molecular Remission Does Not Allow the Prediction of Relapse After Discontinuation of Imatinib In Chronic Myeloid Leukemia

Blood, 2010-11, Vol.116 (21), p.2298-2298

2010

Link zum Volltext

Verfügbarkeit prüfen

Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission

Haematologica (Roma), 2022-12, Vol.107 (12), p.2944

2022

Link zum Volltext

Verfügbarkeit prüfen

Budget Impact of Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia With Sustained Deep Molecular Response

Value in health, 2021-05, Vol.24 (5), p.683-690

2021

Link zum Volltext

Verfügbarkeit prüfen

The pharmacogenetics of imanitib

Genome medicine, 2010-11, Vol.2 (11), p.85-85

2010

Link zum Volltext

Verfügbarkeit prüfen

A single center evaluation of cost savings related to treatment‐free remission in chronic myeloid leukemia patients: the prerequisites of a pharmaco‐economy larger study

British journal of haematology, 2020-05, Vol.189 (3), p.e97-e100

2020

Link zum Volltext

Verfügbarkeit prüfen

Novel analytical methods to interpret large sequencing data from small sample sizes

Human genomics, 2019-08, Vol.13 (1), p.41-11, Article 41

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 91

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(89)
Mit Volltextzugriff
(78)

Publikationsform

Artikel
(90)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(45)
Life Sciences & Biomedicine
(44)
Humans
(37)
Hematology
(27)
Male
(22)
Female
(19)
Chronic Myeloid Leukemia
(18)
Middle Aged
(18)
Adult
(17)
Life Sciences
(17)
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Drug Therapy
(16)
Aged
(14)
Leukemia
(14)
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Genetics
(12)
Oncology
(12)
Protein Kinase Inhibitors - Therapeutic Use
(11)
Fusion Proteins, Bcr-Abl - Genetics
(10)
Imatinib
(10)
Remission
(10)
Young Adult
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group

Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors

Relevance of treatment‐free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitors

Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era: the French experience

Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission

Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study

S155: PROGNOSTIC FACTORS FOR 3‐YEAR MAJOR MOLECULAR RESPONSE MAINTENANCE IN CHRONIC MYELOID LEUKAEMIA PATIENTS IN THE EUROPEAN STOP KINASE INHIBITORS (EURO‐SKI) TRIAL

Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta‐analysis of studies over the last ten years

A case of acute promyelocytic leukaemia with unusual cytological features and a ZBTB16‐RARA fusion gene

Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells

Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia

Deep molecular responses for treatment‐free remission in chronic myeloid leukemia

Achieving a Complete Molecular Remission Under Imatinib Therapy Is Associated with a Better Outcome in Chronic Phase Chronic Myeloid Leukaemia Patients On Imatinib Frontline Therapy

Transient abnormal myelopoiesis (TAM) in a neonate without Down syndrome

Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment‐free remission period after imatinib discontinuation: Results of the French Nilo post‐STIM study

A More Sensitive RQ-PCR to Assess Complete Molecular Remission Does Not Allow the Prediction of Relapse After Discontinuation of Imatinib In Chronic Myeloid Leukemia

BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis

Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission

Budget Impact of Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia With Sustained Deep Molecular Response

The pharmacogenetics of imanitib

A single center evaluation of cost savings related to treatment‐free remission in chronic myeloid leukemia patients: the prerequisites of a pharmaco‐economy larger study

Novel analytical methods to interpret large sequencing data from small sample sizes

Suchergebnisse filtern